Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Leu JH, Miao X, Shalayda K, Coe KJ, Kahnt A, Wu B, Schnarr M, Franks C, Devlin J, Yang TY, Palmer JA, Zhang M, Zhou H, Van Damme W, Smets S, Aguilar Z, Chaplan SR. Leu JH, et al. Clin Pharmacol Drug Dev. 2023 Jun;12(6):611-624. doi: 10.1002/cpdd.1253. Epub 2023 May 1. Clin Pharmacol Drug Dev. 2023. PMID: 37125450 Clinical Trial.
Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn.
Komatsu Y, Verweij EJTJ, Tiblad E, Lopriore E, Oepkes D, Agarwal P, Lam E, Leu JH, Ling LE, Nelson RM, Olusajo V, Saeed-Khawaja S, Tjoa ML, Zhou J, Amin U, Sirah W, Moise KJ. Komatsu Y, et al. Among authors: leu jh. Am J Perinatol. 2024 Sep 17. doi: 10.1055/a-2404-8089. Online ahead of print. Am J Perinatol. 2024. PMID: 39197469 Free article.
Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn.
Moise KJ Jr, Ling LE, Oepkes D, Tiblad E, Verweij EJTJ, Lopriore E, Smoleniec J, Sachs UJ, Bein G, Kilby MD, Miller RS, Devlieger R, Audibert F, Emery SP, Markham K, Norton ME, Ocón-Hernández O, Pandya P, Pereira L, Silver RM, Windrim R, Streisand JB, Leu JH, Mirza A, Smith V, Schwartz LB, Tjoa ML, Saeed-Khawaja S, Komatsu Y, Bussel JB; UNITY Study Group. Moise KJ Jr, et al. Among authors: leu jh. N Engl J Med. 2024 Aug 8;391(6):526-537. doi: 10.1056/NEJMoa2314466. N Engl J Med. 2024. PMID: 39115062 Clinical Trial.
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.
Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Alexeeva E, Appenzeller S, Chasnyk V, Griffin T, Suarez CN, Knupp-Oliveira S, Zeft A, Aviel YB, De Ranieri D, Gottlieb BS, Levy DM, Rabinovich CE, Silva CA, Spivakovsky Y, Uziel Y, Ringold S, Xu XL, Leu JH, Lam E, Wang Y, Lovell DJ, Martini A, Ruperto N; Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO). Brunner HI, et al. Among authors: leu jh. J Rheumatol. 2024 Nov 1;51(11):1125-1134. doi: 10.3899/jrheum.2024-0298. J Rheumatol. 2024. PMID: 39089836 Free article. Clinical Trial.
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.
Taylor PC, Schett G, Huizinga TW, Wang Q, Ibrahim F, Zhou B, Liva SG, Shaik JSB, Xiong Y, Leu JH, Panchakshari RA, Loza MJ, Ma K, Dhatt H, Rojo Cella R, Karyekar CS, Cuff CA, Gao S, Fei K. Taylor PC, et al. Among authors: leu jh. RMD Open. 2024 Jun 28;10(2):e004278. doi: 10.1136/rmdopen-2024-004278. RMD Open. 2024. PMID: 38942592 Free PMC article. Clinical Trial.
75 results